About CLINUVEL

Webcasts

New Treatment Inspires Hope for the Battle Against Sun Allergy

11 Nov 2015
Coverage of erythropoietic protoporphyria on Good Morning America, July 2015.

Dateline - "Out of the Shadows"

11 Nov 2015
In June 2015, US broadcaster NBC reported on the impact of rare light disorders, including erythropoietic protoporphyria, on patients and their families.

What can vitiligo patients do? - Lee Thomas and Dr Philippe Wolgen, Part 4

07 Sep 2012
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, CLINUVEL ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy. Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community. In this four part video series, shot in early 2012, he interrogated CLINUVEL’s CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo.

The future of vitiligo treatment - Lee Thomas and Dr Philippe Wolgen, Part 3

15 Aug 2012
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, CLINUVEL ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy. Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community. In this four part video series, shot in early 2012, he interrogated CLINUVEL's CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo. Learn more about CLINUVEL's vitiligo program.

Vitiligo trials of SCENESSE® - Lee Thomas and Dr Philippe Wolgen, Part 2

06 Aug 2012
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, CLINUVEL ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy. Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community. In this four part video series, shot in early 2012, he interrogated CLINUVEL's CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo. Learn more about CLINUVEL's vitiligo program.

SCENESSE® and its use in vitiligo - Lee Thomas and Dr Philippe Wolgen, Part 1

06 Aug 2012
Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, CLINUVEL ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy. Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community. In this four part video series, shot in early 2012, he interrogated CLINUVEL’s CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo. Learn more about CLINUVEL's vitiligo program

Liver transplantation in erythropoietic protoporphyria (EPP)

29 May 2012
Erythropoietic protoporphyria (EPP) is a rare disease causing absolute intolerance of skin to light. In about 5% of EPP cases, patients also experience liver failure, requiring a life saving liver transplant. Florence, an immunology PhD, career scientist and EPP patient, underwent a liver transplant in 1989 following a liver failure due to her EPP. In early 2012 Florence shared her story on camera, discussing her transplantation in depth. CLINUVEL is very grateful to Florence for being able to share this online.

Understanding Vitiligo: Misconception & Myth

05 Mar 2012
Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide, common understanding of vitiligo has been clouded by misconceptions, leading to the stigmatization of those affected by the disease. Modern medical understanding easily corrects much of this misunderstanding. In presenting this information we hope to facilitate a better common understanding of vitiligo, and to help people gain an insight into this distressing disorder. Produced March 2012. Learn more about CLINUVEL's vitiligo program. Quote references: Vitiligo Support International:http://www.vitiligosupport.org/vitiligo/ Kaimal & Thappa, (2010). "Diet in Dermatology". IJDVL 76(2):103-115. Available online:http://www.ijdvl.com/article.asp?issn=0378-6323;year=2010;volume=76;issue=2;spage=103;epage=115;aulast=Kaimal Gauthier & Benzekir in Picardo & Taieb (2010). "Vitiligo". Springer (1st edition). Image references: http://commons.wikimedia.org/wiki/File:Vitiligo1.JPG http://commons.wikimedia.org/wiki/File:Vitiligo2.JPG Selected images courtesy of Pearl E Grimes MD Our thanks to…

'Check up' reports on rare disease EPP and SCENESSE® (afamelanotide)

27 Feb 2012
On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes absolute intolerance of skin to sunlight, and CLINUVEL’s novel drug SCENESSE® (afamelanotide), which has been trialed as a photoprotective in EPP. CLINUVEL has subtitled the 'Check up' program and re-released for the broader EPP community.All footage and soundtrack are copyright © Telezueri 2012.

"Focus really pays off in the end"

25 Feb 2012
Following CLINUVEL's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medicines Agency, CEO Dr Philippe Wolgen discusses the challenges to date and what may lie ahead for CLINUVEL.
Page 1 of 4

Quick Links